# Breast Mass Revealing Hidden Lung Cancer

**Authors:** Betsalel Adout, Imad Karam, Kafi Thomas, Sayed Ali, Aye M Thida, Sayra Ilyas, Rachelle Hamadi, Shoushtari Alavi, Maksim Agaronov, Edwin Chiu

PMC · DOI: 10.7759/cureus.77429 · Cureus · 2025-01-14

## TL;DR

A breast mass in a 62-year-old woman revealed metastatic lung cancer, highlighting the importance of accurate diagnosis and personalized treatment.

## Contribution

This case highlights the rare occurrence of lung cancer metastasizing to the breast and emphasizes the role of imaging and phylogenetic analysis in diagnosis and treatment.

## Key findings

- A breast mass was found to be metastatic lung adenocarcinoma through immunohistochemistry and imaging.
- The patient responded to treatment with stable disease per RECIST criteria.
- Phylogenetic analysis can provide insights into tumor evolution and metastasis.

## Abstract

Lung cancer is the second most common cancer and the leading cause of cancer-related deaths in the United States, frequently metastasizing to the brain, bones, liver, and adrenal glands. However, it is uncommon for lung malignancies to metastasize to the breast, and is generally assumed to carry a poor prognosis.

We present the case of a 62-year-old female who presented for an annual physical exam and complained of persistent neck pain without neurological deficit. A screening mammogram revealed a 0.4 cm right breast mass. A biopsy of the mass showed carcinoma with micropapillary features. Immunohistochemistry was positive for cytokeratin (CK) 7 and thyroid transcription factor 1 (TTF-1)and negative for estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2), indicating a primary lung origin. Next-generation sequencing (NGS) was negative for a targetable mutation. The patient was treated for metastatic lung adenocarcinoma with carboplatin, pemetrexed, and pembrolizumab for 4 cycles followed by maintenance with pemetrexed and pembrolizumab. Per response evaluation criteria in solid tumors (RECIST) the patient continues to have stable disease.

Imaging and immunohistochemistry (IHC) are critical in differentiating between primary and metastatic lesions. Additionally, using phylogenetic analysis to understand tumor evolution allows for valuable insights into how metastases develop and spread, thus assisting in personalized treatment strategies. Early and accurate diagnosis is essential for appropriate treatment planning leading to improved patient outcomes.

## Linked entities

- **Chemicals:** carboplatin (PubChem CID 426756), pemetrexed (PubChem CID 135410875)
- **Diseases:** lung cancer (MONDO:0005138)

## Full-text entities

- **Genes:** NKX2-1 (NK2 homeobox 1) [NCBI Gene 7080] {aka BCH, BHC, NK-2, NKX2.1, NKX2A, NMTC1}, TTF1 (transcription termination factor 1) [NCBI Gene 7270] {aka TTF-1, TTF-I}, ERBB2 (erb-b2 receptor tyrosine kinase 2) [NCBI Gene 2064] {aka CD340, HER-2, HER-2/neu, HER2, MLN 19, MLN-19}, PGR (progesterone receptor) [NCBI Gene 5241] {aka NR3C3, PR}, ESR1 (estrogen receptor 1) [NCBI Gene 2099] {aka ER, ESR, ESRA, ESTRR, Era, NR3A1}
- **Diseases:** cancer (MESH:D009369), neurological deficit (MESH:D009461), Lung Cancer (MESH:D008175), lung adenocarcinoma (MESH:D000077192), Breast Mass (MESH:D061325), neck pain (MESH:D019547), metastases (MESH:D009362)
- **Chemicals:** carboplatin (MESH:D016190), pembrolizumab (MESH:C582435), pemetrexed (MESH:D000068437)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC11825228/full.md

## Figures

3 figures with captions in the complete paper: https://tomesphere.com/paper/PMC11825228/full.md

## References

22 references — full list in the complete paper: https://tomesphere.com/paper/PMC11825228/full.md

---
Source: https://tomesphere.com/paper/PMC11825228